A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization

• Main Authors: Kuan, Jew Win, Anselm, Su Ting, SP, Wong, XY, Sim, SG, Toh, TC, Ong, JS, Rajasuriar, SH, Lim, YK, Guan, HK, Liew, PK, Liew, JT, Tan, AN, Kori, YY, Cheng, SM, Tan, KM, Chang
• Format: Article
• Language: English
• Published: Elsevier 2015
• Subjects: RZ Other systems of medicine
• Online Access: http://ir.unimas.my/id/eprint/36151/1/filgrastim1.pdf; http://ir.unimas.my/id/eprint/36151/; https://www.trasci.com/article/S1473-0502(15)00061-0/fulltext; http://dx.doi.org/10.1016/j.transci.2015.03.017

There are few randomized trials comparing filgrastim and pegfilgrastim in peripheral blood stem cell mobilization (PBSCM). None of the trials studied the effects of the timing of pegfilgrastim administration on the outcomes of mobilization. We conducted a randomized triple blind control trial comparing the outcomes of filgrastim 5 microg/kg daily from day 3 onwards, 'early' pegfilgrastim 6 mg on day 3 and 'delayed' pegfilgrastim 6 mg on day 7 in cyclophosphamide PBSCM in patients with no previous history of mobilization. Peripheral blood (PB) CD34+ cell count was checked on day 8 and day 11 onward. Apheresis was started when PB CD34+ >/= 10/microl from day 11 onward. The primary outcome was the successful mobilization rate, defined as cumulative collection of >/=2 x 10(6)/kg CD34+ cells in three or less apheresis. The secondary outcomes were the day of neutrophil and platelet engraftment post transplantation. There were 156 patients randomized and 134 patients' data analyzed. Pegfilgrastim 6 mg day 7 produced highest percentage of successful mobilization, 34 out of 48 (70.8%) analyzed patients, followed by daily filgrastim, 28 out of 44 (63.6%) and day 3 pegfilgrastim, 20 out of 42 (47.6%) (p = 0.075). Pegfilgrastim day 7 and daily filgrastim reported 1.48 (p = 0.014) and 1.49 (p = 0.013) times higher successful mobilization rate respectively as compared to pegfilgrastim day 3 after adjusting for disease, gender and exposure to myelotoxic agent. Multiple myeloma patients were three times more likely to achieve successful mobilization as compared to acute leukemia or lymphoma patients. Pegfilgrastim avoided the overshoot of white cells compared to filgrastim. There was no difference in the duration of both white cells and platelet recovery post transplantation between the three interventional arms.